Global market leader in molded glass packaging solutions for the pharmaceutical industry, SGD Pharma, has published its latest Corporate Social Responsibility (CSR) Report 2022 to underscore its company-wide commitment to a green and sustainable present and future. The 2022 Report is published soon after the company received its coveted ECOVADIS Gold award, achieving its highest ever score of 75 out of 100 - the company is currently rated in the top 2% of global companies in the ‘Manufacture of glass and glass products’ category.
Key achievements include:
100% of all SGD Pharma owned glass manufacturing plants are ISO 45001 certified
100% of SGD Pharma sites are certified with ISO 14001
100% of critical suppliers have CSR clauses in their contracts
Average 26 hours of training per employee
>20% reduction in water consumption vs 2020
The company-wide focus on CSR under new CEO Olivier Rousseau and with new investors PAI Partners on board means stretch targets have been set ahead:
35% reduction in carbon footprint by 2030
65% reduction in carbon footprint by 2040 (compared with 2020 baseline)
Goal: Zero accidents
SA 8000 certification of our plant in India
CSR Spotlight: SGD Pharma Zhanjiang China – tackling deforestation
As well as being SA 8000 certified, the SGD Pharma China plant in Zhanjiang supports the local community by helping to protect biodiversity in Zhanjiang. The city is home to one of the world’s most successful examples of wetland ecological restoration and SDG Pharma has committed to supporting efforts to tackle deforestation by planting mangrove trees. By the end of 2022, SGD Pharma planted a total of 1300 mangrove trees on the coast of Zhanjiang, China, in association with Zhanjiang Nature and Resource Bureau.
CSR Spotlight: SGD Pharma Vemula India – developing local schools
SGD Pharma India is actively involved in social responsibility programs and contributes to developing villages and schools in the region of its plant in Vemula, Telangana, India. During one of the CSR events, SGD Pharma India distributed 200 bicycles for students and 20 special scooters to physically challenged residents.
As a global leader in heavy manufacturing of pharmaceutical-grade glass, SGD Pharma takes its global and local responsibilities seriously. Each location has an energized CSR plan deployed locally and conforms to the company’s overall standards.
The company has made significant BAT (best available technology) investment in its global plants and infrastructure as part of a continual search for improvements in energy consumption. This includes furnace renovations and updated glass production facilities in all 5 plants, including furnace 2 in Sucy-en-Brie, France (leading to a reduction in C02 and Nox emissions) and Saint-Quentin-La-Motte, France, which has both a full electrical furnace and a second oxy-fuel combustion furnace equipped with electrical boosting, both of which allow the plant to produce glass with low carbon emissions. SGD Pharma has also committed to uplift its decarbonization investment by 20% over the coming 15 years.
28.06.2023, SGD Pharma
此网站新闻材料的版权属于公司或第三方的新闻提供者，其所有权利保留。所有新闻材料对其访问者只能限于其本人使用，并且使用此材料的风险由其使用者独自自行承担。严禁对新闻材料进行再次发布和其它商业利用. 作为商业贸易的用途。如果新闻材料由第三方提供，当应用此新闻材料时，每个使用者都同意遵守，并且受此特定的项目的约束。Glass Global并不代表及认可新闻材料中所包含的内容及新闻中的外部网站的内容的准确性及可靠性。
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.